false
0001739940
0001739940
2024-02-15
2024-02-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
February 14, 2024
The Cigna Group
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation) |
001-38769
(Commission File Number) |
82-4991898
(IRS Employer
Identification No.) |
900 Cottage Grove Road
Bloomfield, Connecticut 06002
(Address of principal executive offices) (Zip
Code)
Registrant’s telephone number, including area
code:
(860) 226-6000
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, Par Value $0.01 |
CI |
New York Stock Exchange, Inc. |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
On February 14, 2024, The Cigna
Group (“Cigna” or the “Company”) entered into accelerated share repurchase agreements (collectively, the “ASR
Agreements”) with Deutsche Bank AG and Bank of America, N.A. (collectively, the “Dealers”). Under the ASR Agreements,
the Company will purchase an aggregate of $3.2 billion of the Company’s common stock as part of its existing share repurchase program.
Under the terms of the ASR Agreements,
on February 15, 2024, Cigna will receive an aggregate initial delivery of approximately 7.6 million shares in exchange for a prepayment
of $3.2 billion. The specific number of shares that the Company will ultimately repurchase under the ASR Agreements will be determined
based on the volume-weighted average price of Cigna’s common stock during the terms of the transactions, less a discount and subject
to adjustments pursuant to the terms and conditions of the ASR Agreements.
At final settlement, under certain
circumstances the Dealers may be required to deliver additional shares of Cigna common stock to the Company, or in other circumstances,
Cigna may be required to deliver, at its discretion, either shares of its common stock or cash to the Dealers. Final settlement of the
ASR Agreements is expected to occur during the second quarter of 2024.
The ASR Agreements contain customary
terms for these types of transactions, including, but not limited to, the mechanisms to determine the number of shares or the amount of
cash that will be delivered at final settlement, the required timing of delivery of the shares, the specific circumstances under which
final settlement of the transactions may be accelerated or extended or the ASR Agreements may be terminated early by Cigna or the Dealers,
and various acknowledgments, representations and warranties made by the Company and the Dealers to one another. The terms of the ASR Agreements
are subject to adjustment under certain circumstances.
Each of the Dealers perform normal
banking, investment banking and/or advisory services for Cigna from time to time for which they receive customary fees and expenses.
On February 15, 2024, the Company
issued a press release announcing its entry into the ASR Agreements with the Dealers. A copy of the press release is filed as Exhibit
99.1 to this Current Report on Form 8-K and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
the Cigna group
|
Date: February 15, 2024 |
By: |
/s/ Brian C. Evanko |
|
|
Brian C. Evanko |
|
|
Executive Vice President and Chief Financial Officer and President and Chief Executive Officer, Cigna Healthcare |
|
|
|
|
|
|
Exhibit 99.1
Press Release
The Cigna Group Announces $3.2 Billion Accelerated
Stock Repurchase
Bloomfield, Conn. February 15, 2024 – Global health
company The Cigna Group (NYSE: CI) will repurchase $3.2 billion of common stock through accelerated stock repurchase agreements (the “ASR
Agreements”) with Deutsche Bank AG and Bank of America, N.A. (the “Counterparties”). The ASR Agreements are
part of The Cigna Group’s (the “Company”) existing share repurchase program, which had remaining authority
of $10.6 billion as of February 13, 2024.
“This accelerated share repurchase represents a value-enhancing
deployment of capital,” said David M. Cordani, Chairman and Chief Executive Officer, The Cigna Group. “This is a testament
to the ongoing growth and strength of our businesses, and we remain committed to returning significant value to our shareholders and investing
in our future. We are on track to repurchase $5 billion of common stock over the first half of 2024, inclusive of this accelerated share
repurchase, and continue to expect the majority of discretionary cash flow to be used for share repurchase this year.”
Under the terms of the ASR Agreements, on February 15, 2024, the Company
will receive an aggregate initial delivery of approximately 7.6 million shares in exchange for a prepayment of $3.2 billion. The specific
number of shares that the Company ultimately will repurchase pursuant to the ASR Agreements will be based generally on the daily volume-weighted
average share price of The Cigna Group common stock over the term of the ASR Agreements, less a discount and subject to adjustments pursuant
to the terms and conditions of the ASR Agreements. Final settlement under the ASR Agreements is expected to occur in the second quarter
of 2024. The ASR Agreements contain provisions customary for agreements of this type, including provisions for adjustments to the transaction
terms upon certain specified events, the circumstances generally under which final settlement of the ASR Agreements may be accelerated
or extended or the ASR Agreements may be terminated early by the Company or the Counterparties, and various acknowledgements and
representations made by the parties to each other. At final settlement, under certain circumstances, the Company may be entitled to receive
additional shares of The Cigna Group common stock from the Counterparties or the Company may be required to make a cash payment or,
if the Company elects, deliver shares of The Cigna Group common stock to the Counterparties. All of the shares of The Cigna Group
common stock delivered to the Company under the ASR Agreements will be held in treasury or retired.
About The Cigna Group
The Cigna Group (NYSE: CI) is a global health company committed to creating a better future built on the vitality of every individual
and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes
products and services marketed under Evernorth Health Services, Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales
capabilities in more than 30 countries and jurisdictions, and has approximately 165 million customer relationships around the world. Learn
more at www.thecignagroup.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS
This press release, and oral statements made in connection with this release,
may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements
are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are
not historical facts. Forward-looking statements may include, among
others, statements concerning the number of shares that ultimately will
be repurchased under the ASR Agreements and other statements regarding our future beliefs, expectations, plans, intentions, liquidity,
cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe,"
"expect," "project," "plan," "intend," "anticipate," "estimate," "predict,"
"potential," "may," "should," "will" or other words or expressions of similar meaning, although
not all forward-looking statements contain such terms.
Forward-looking statements are subject to risks and uncertainties,
both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements.
The discussions in our Annual Report on Form 10-K for the year ended December 31, 2022, including the “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” sections therein, as such discussions may be updated from
time to time in our periodic filings with the Securities and Exchange Commission, include both expanded discussion of these factors and
additional risk factors and uncertainties that could affect the matters discussed in the forward-looking statements. You should not place
undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance
or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes
no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except
as may be required by law.
INVESTOR RELATIONS CONTACT:
Ralph Giacobbe
(860) 787-7968
ralph.giacobbe@TheCignaGroup.com
MEDIA
CONTACT:
Justine Sessions
(860) 810-6523
justine.sessions@evernorth.com
v3.24.0.1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Cigna (NYSE:CI)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Cigna (NYSE:CI)
Historical Stock Chart
Von Mai 2023 bis Mai 2024